BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35914158)

  • 1. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
    Chan CY; Chiu DK; Yuen VW; Law CT; Wong BP; Thu KL; Cescon DW; Soria-Bretones I; Cheu JW; Lee D; Tse AP; Zhang MS; Tan KV; Ng IO; Khong PL; Yau TC; Bray MR; Mak TW; Wong CC
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2119514119. PubMed ID: 35914158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
    Chan CY; Yuen VW; Chiu DK; Goh CC; Thu KL; Cescon DW; Soria-Bretones I; Law CT; Cheu JW; Lee D; Tse AP; Tan KV; Zhang MS; Wong BP; Wong CM; Khong PL; Ng IO; Bray MR; Mak TW; Yau TC; Wong CC
    Hepatology; 2023 Mar; 77(3):729-744. PubMed ID: 35302667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
    Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TTK Inhibitors as a Targeted Therapy for
    Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
    Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
    Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
    Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
    PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
    Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
    Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
    Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
    Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
    Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.
    Liu X; Liao W; Yuan Q; Ou Y; Huang J
    Oncotarget; 2015 Oct; 6(33):34309-20. PubMed ID: 26418879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    Kim KJ; Lee HW; Seong J
    J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
    Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
    Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
    Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
    Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
    Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
    Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.